United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Incyte

Merck

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

Which stock wins in a matchup between these two giant drugmakers?

Better Buy:  Pfizer vs.  Merck

Apple

Chevron

Exxon Mobil

Walgreens

Six of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.

Apple, Chevron, Exxon, Pfizer and More Dow Earnings Coming This Week

OPKO Health

Opko Health Inc. shares OPK, -3.46% soared 21% in premarket trade Monday, while Pfizer Inc.

Opko and Pfizer announce positive results in late-stage trial of human growth hormone treatment

— Results demonstrated potential to reduce current dosing frequency from once-daily to a single weekly injection —

OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency

Eli Lilly

These aren't the highest payouts in the industry, but they have the best chance to steadily climb.

3 Dividend-Paying Pharma Stocks to Buy Now

AbbVie

Gilead Sciences

High dividend yields. Solid long-term prospects.

3 Top Healthcare Dividend Stocks That Are Great Picks for Retirees

Pfizer announced that it had licensed the antisense drug AKCEA-ANGPTL3-LRx from Akcea with a $250 million upfront license fee.

Pfizer's Push For Antisense Licensing Is Closely Aligned With Current Target Indications

Johnson & Johnson

UnitedHealth Group

Health Care Select Sector SPDR Fund

The stock market is having a banner year, despite the trade war with China and worries about a looming economic slowdown. But health care stocks aren't taking part in the rally.

Glum days have arrived for health care stocks

Could these biopharmaceutical giants continue growing if they stopped hiking up drug prices?

3 Big Pharma Stocks Driving Price Inflation

Intel

Microsoft

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components.

5 Most Shorted Dow Stocks

Pfizer (PFE) closed the most recent trading day at $35.44, moving -1.1% from the previous trading session.

Pfizer (PFE) Stock Moves -1.1%: What You Should Know

Broadcom

BHP Billiton

HSBC Holdings

Union Pacific

While gurus hold positions in these companies, their share prices and returns continue to decline.

5 Underperforming Gurus' Stocks

Cisco Systems

JPMorgan Chase & Co

Coca-Cola

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The eight “Dogs of the Dow” for 2019 had an aggregate year-to-date gain of 10% at the end of September versus 13.9% for the Dow Jones Industrial Average.

Cisco, Chevron And The Other 'Dogs Of The Dow' Continue To Underperform The DJIA

Akcea Therapeutics

Akcea and Ionis to earn $250 million license fee Akcea and Ionis to earn $250 million license fee

Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

Pfizer’s Lyrica is the leader in the anti-epileptic drugs market. Epilepsy is a condition in which a person has recurrent seizures.

Pfizer’s Lyrica In the Anti-Epileptic Drugs Market

Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.

Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study

Caterpillar

With just over one quarter left in 2019, it has been another banner year for stock market investors, with double-digit gains in all three major averages.

5 Dow Jones Industrial Average 2019 Laggards Could Be Big Q4 Winners

Which stock wins in a matchup between these two big drugmakers?

Better Buy:  Gilead Sciences vs. Pfizer

Pfizer Inc  said on Friday Ian Read will retire as executive chairman at the end of this year, after a four-decade association with the largest U.S. drugmaker that included eight years as chief executive officer.

Pfizer veteran Ian Read to retire as executive chairman

Pfizer Inc. shares rose 1.3% in premarket trade Friday, after the drug giant reported positive results in a second late-stage trial of a treatment for moderate to severe atopic dermatitis, a chronic skin disease.

Pfizer shares up 1.3% premarket after reporting positive results in second trial of dermatitis treatment

GlaxoSmithKline

Novo Nordisk

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

when stocks turn up that see insider buying, and are also top ranked, investors are wise to take notice. One such company is Pfizer

Pfizer Named Top Dividend Stock With Insider Buying and 4.00% Yield

Taiwan Semiconductor Manufacturing

As of Friday, the following long-term dividend payers offer a forward dividend yield that tops the S&P 500 index's yield of 1.87% significantly.

These 3 Long-Term Dividend Payers Offer a High Forward Yield

News for Pfizer Stock (PFE)